Voyager Therapeutics to Present Alzheimer’s Data in Boston
The company will showcase research on two new investigational Alzheimer’s treatments at a medical conference in November 2026.
Updated on Oct. 27, 2026 in Alzheimer’s
Live Poll
Will new clinical research provide more effective treatments for Alzheimer's patients in the near future?
Voyager Therapeutics plans to present new data regarding its investigational Alzheimer’s treatments at the 19th Clinical Trials on Alzheimer’s Disease Conference. The research presentations are scheduled to take place in Boston from November 16 to November 17, 2026.
Why it matters
The upcoming presentations offer a look at potential new therapeutic approaches to managing Alzheimer’s disease. These findings contribute to the ongoing development of treatments aimed at addressing the pathology of the condition.
The conference will feature the presentation of research findings for VY1706, a gene therapy, and VY7523, a monoclonal antibody. The data will be displayed via poster #P055 and #P054 respectively at the 19th annual conference.
The players
Voyager Therapeutics
This biotechnology company focuses on developing gene therapies and other treatments for neurological diseases.
Elena Ratti
She serves as a presenter for the research findings at the 19th Clinical Trials on Alzheimer’s Disease Conference.
The details
Elena Ratti will present the findings on behalf of Voyager Therapeutics at the upcoming conference. These research data points will be made available through the company website for public review.
Timeline
The 19th Clinical Trials on Alzheimer’s Disease Conference will occur in Boston from November 16-19, 2026.
Poster presentations are scheduled to begin on November 16, 2026, at 2:00 p.m.
The poster presentation session concludes on November 17, 2026, at 5:30 p.m. ET.
The Big Picture
The research updates follow the rigorous evidentiary standards set by the 19th Clinical Trials on Alzheimer's Disease Conference. This appearance marks a step in the company's broader clinical development cycle for its tau-focused Alzheimer's candidates.
These presentations provide early insight into experimental therapies that could eventually expand treatment options for patients with Alzheimer's disease. Results from these research findings will help inform future clinical development steps and potential patient access.
The takeaway
The upcoming conference provides a platform for the disclosure of new data regarding the company’s tau-lowering therapies. Readers can track these developments to understand the future direction of neurodegenerative disease research.
Further reading
For more information on current developments, visit the Alzheimer’s section.
More information
For detailed documentation, visit the Voyager Therapeutics science publications portal.
Live Poll
Will new clinical research provide more effective treatments for Alzheimer's patients in the near future?
